Miguel Arturo Pavlovsky

Author

Fundación para la Investigación, Docencia y Prevención del Cáncer ORCID

Also Known As

M PAVLOVSKY, M Pavlovsky, M Pavlovský, M. A. Pavlovsky, M. Pavlovsky, M.A. Pavlovsky, Miguel A Pavlovsky, Miguel A. Pavlovsky, Miguel Arturo Pavlovsky, Miguel Pavlovsky

123

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Fundación para la Investigación, Docencia y Prevención del Cáncer Universitair Ziekenhuis Leuven University of Cologne Hospital Universitario de La Princesa University Hospital Hradec Králové

About

Miguel Arturo Pavlovsky is an author at Fundación para la Investigación, Docencia y Prevención del Cáncer specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	496
2	Immunology	3	3	441
3	Health Sciences	2	2	36
4	Cell Biology	1	1	15
5	Nephrology	1	1	37

Miguel Arturo Pavlovsky

Publications

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan, The Lancet Oncology Lymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyPathology	2015	408
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma Graeme Fraser, Paula Cramer, Rodrigo Santucci Alves da Silva, Leukemia	2018	116
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, Leukemia	2021	94
Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study Vânia Hungria, Carlos Chiattone, Miguel Arturo Pavlovsky, Journal of Global Oncology	2019	75
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, New England Journal of Medicine	2025	65
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Graeme Fraser, Asher Chanan‐Khan, Fatih Demırkan, Leukemia & lymphoma/Leukemia and lymphoma	2020	41
Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: Prospective observations of an emerging syndrome Miguel Arturo Pavlovsky, Robert S. Weinstein Journal of Clinical Apheresis Dialysis TherapySurgeryCoronary Artery DiseaseProgressive SyndromeThrombosis	1997	37
Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience Mariel Emilce Alejandre, Leticia Madalena, Miguel Arturo Pavlovsky, Clinical Chemistry and Laboratory Medicine (CCLM)	2010	34
Increased immature hematopoietic progenitor cells CD34<sup>+</sup>/CD38<sup>dim</sup> in myelodysplasia Mariela Monreal, María Laura Pardo, Miguel Arturo Pavlovsky, Cytometry Part B Clinical Cytometry	2006	27
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma Loretta J. Nastoupil, Miguel Arturo Pavlovsky, Iwona Danielewicz, Blood Advances	2023	22

Page 1